Oncology

FTC Inquiry Into PBMs to Include a Look at Specialty Drug Lists

June 9th 2022

By Mary Caffrey

The Federal Trade Commission (FTC) will require the 6 largest pharmacy benefit managers (PBMs) to submit records and answer questions regarding their business practices.

ASCO Posters Reveal Successful Approaches to Biosimilar Adoption in Oncology

June 6th 2022

Posters presented at the American Society of Clinical Oncology (ASCO)'s annual meeting showed the successful approaches health systems took to encourage greater adoption of oncology biosimilars.

FDA Approves Fifth Pegfilgrastim Biosimilar, Fylnetra

June 1st 2022

By Skylar Jeremias

The FDA approved Fylnetra, the fifth approval for a pegfilgrastim biosimilar in the United States.

Biosimilar Business Recap: CHMP Rejects Herceptin Biosimilar; Prime Therapeutics Biosimilar Success; Archigen Biotech Liquidation

May 26th 2022

By Skylar Jeremias

The European Committee for Medicinal Products (CHMP) rejects Prestige Biopharma’s biosimilar referencing Herceptin; Prime Therapeutics’ plan to leverage biosimilars resulted in savings for patients; Samsung Biologics and AstraZeneca liquidated their joint venture (Archigen Biotech).

Viatris, Biocon Biologics Launch Avastin Biosimilar in Canada

May 23rd 2022

By Skylar Jeremias

Viatris and Biocon Biologics announced the launch of their bevacizumab product, Abevmy, a biosimilar to Avastin, on the Canadian market.

Dr Sonia Oskouei Predicts How Bevacizumab Use Will Evolve in Ophthalmology

May 22nd 2022

By Skylar Jeremias

The use of bevacizumab products for ophthalmic conditions will continue to evolve as the market grows. However, off-label usage will likely be the norm, according to Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health, at Asembia’s Specialty Pharmacy Summit.

Contributor: No Good Deed Goes Unpunished—How PBM Mandates Increase Practice Variability

May 17th 2022

By Jeff Patton, MD

Jeff Patton, MD, CEO and board member at OneOncology, dived into the controversial role that pharmacy benefit managers (PBMs) play in formulary decision-making and how PBMs impact biosimilar utilization.

Conference Posters Highlight Real-world Trends of Biosimilars, Reclassified Biologics

May 14th 2022

By Skylar Jeremias

Posters from the Academy of Managed Care Pharmacy (AMCP)’s annual meeting examined the real-world patterns of biosimilar utilization and the impact of products that have been reclassified as biologics on Medicaid spending.

Coherus Biosciences Terminates Deal With Innovent for Avastin Biosimilar

May 6th 2022

By Skylar Jeremias

During the Coherus Biosciences earnings call, the company announced that it was terminating its licensing agreement with Innovent Biologics for Byvasda, a bevacizumab biosimilar candidate referencing Avastin.

Medicare Policies Must Fix Cost Sharing Under Part D, Expert Writes

May 4th 2022

By Mary Caffrey

Stacie B. Dusetzina, PhD, is the Ingram Associate Professor of Cancer Research at Vanderbilt University Medical Center, and a member of the editorial board for The American Journal of Managed Care®.